Skip to content
CancerIndex

Publication

Safe Accelerated Venetoclax Escalation: a phase 1b study of obinutuzumab plus venetoclax with daily ramp-up in CLL.

Jennifer L Crombie, Inhye E Ahn, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Mari Kniezewski, Samantha Normilus, Shantal Solomon, Josie Montegaard, Austin I Kim, Reid W Merryman, Philippe Armand, David C Fisher, Jennifer R Brown, Matthew S Davids

Blood advancesSep 8, 2026PMID 42335220doi:10.1182/bloodadvances.2026020392 PMC13558240Journal ArticleClinical Trial, Phase IpubmedProvenance
Source
PubMed
Retrieved
Sep 19, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260919-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Although venetoclax-based regimens are highly effective for patients with chronic lymphocytic leukemia (CLL), initiation is complex because of the requirement of a 5-week dose ramp-up used to mitigate the risk of tumor lysis syndrome (TLS). We report the results of the first prospective study of…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 1

Registered trialsNCT04843904

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.